Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Kairos Pharma, Ltd.: Kairos Pharma Closing of $6.2 Million Initial Public Offering | 62 | GlobeNewswire (Europe) | LOS ANGELES, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. ("Kairos Pharma" or the "Company") (NYSE American: KAPA), a clinical stage biopharmaceutical company developing cancer therapeutics... ► Artikel lesen | |
Di | Kairos Pharma, LTD. - 8-K, Current Report | 2 | SEC Filings | ||
Di | Micro-cap cancer biotech Kairos Pharma prices IPO at $4 | 4 | Renaissance Capital | ||
Mo | Kairos Pharma opens at $4, IPO priced at $4 | 2 | Investing.com | ||
Mo | Kairos Pharma Prices $6.2 Mln IPO At $4 Per Share | 363 | AFX News | WASHINGTON (dpa-AFX) - Kairos Pharma, Ltd. Monday announced the pricing of its initial public offering of 1.55 million shares of common stock at $4.00 per share. The clinical stage company has... ► Artikel lesen | |
Mo | Kairos Pharma Prices 1.55M Share IPO at $4/sh | 2 | Investing.com | ||
Mo | Kairos Pharma prices $6.2M IPO | 1 | Seeking Alpha | ||
Mo | Kairos Pharma, Ltd.: Kairos Pharma Prices $6.2 Million Initial Public Offering | 68 | GlobeNewswire (Europe) | LOS ANGELES, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. ("Kairos Pharma" or the "Company"), a clinical stage biopharmaceutical company developing cancer therapeutics designed to reverse... ► Artikel lesen | |
12.09. | Kairos Pharma, LTD. - 8-A12B, Registration of securities | 1 | SEC Filings | ||
09.09. | IPO Roundup: Bicara Therapeutics, Kairos Pharma and more | 1 | Seeking Alpha | ||
16.08. | Kairos Pharma, LTD. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
20.05. | Kairos Pharma Announces 1.55M Share IPO at $4/sh | 1 | Investing.com | ||
20.05. | Kairos Pharma, LTD. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
11.05. | Kairos Pharma, LTD. - S-1/A, General form for registration of securities | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 41,035 | -0,38 % | QIAGEN N.V.: QIAGEN und Bio-Manguinhos/Fiocruz verbessern Nachweis von Malaria und Dengue-Fieber in Brasiliens nationalem Screening-Programm | Moderne PCR-basierte Screening-Plattform kommt landesweit in 30 Laboren zum Einsatz und bietet neue Möglichkeiten zum Nachweis von Malaria, HIV, HCV und HBV in Blutspenden // Modernste Funktionen unterstützen... ► Artikel lesen | |
BIONTECH | 100,50 | -3,46 % | BioNTech-Rivale: Moderna stürzt ab: Produkte verzögern sich und die Umsatzerwartungen sinken | © Foto: Bodo Schackow/dpaAngetrieben von der Einnahmenschwemme durch den Corona-Impfstoff hat Moderna zahlreiche neue Produkte in Angriff genommen - und scheint sich damit etwas übernommen zu haben.... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 29,510 | +54,99 % | Why Edgewise Therapeutics Stock Is Up 50% on Thursday | ||
EVOTEC | 6,345 | -1,78 % | Evotec Aktie: Gelingt eine Überraschung wie bei HelloFresh? | Es könnte spannend werden bei der Evotec Aktie, bei der zuletzt einige "Insiderkäufe" zu sehen waren, zugleich Shortseller sehr aktiv sind. In einer ähnlichen Konstellation sorgte gestern bei HelloFresh... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 23,140 | -5,74 % | ROUNDUP/Aktien New York: Neue Rekorde vor US-Zinsentscheid | NEW YORK (dpa-AFX) - Vor dem Zinsentscheid der US-Notenbank Fed bleiben die Anleger an den New Yorker Börsen optimistisch. Der Leitindex Dow Jones Industrial markierte am Dienstag gleich zu Beginn... ► Artikel lesen | |
ADMA BIOLOGICS | 19,730 | +2,23 % | ADMA Biologics, Inc.: ADMA Biologics Set to Join S&P SmallCap 600 Index | RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 45,670 | +2,35 % | Unveiling 7 Analyst Insights On Avidity Biosciences | ||
DYNE THERAPEUTICS | 36,420 | +6,18 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
TELESIS BIO | 2,930 | +116,24 % | HotStocks USA: Rezolve AI + 207%, Telesis Bio + 167 % | ||
NUVALENT | 103,21 | +0,44 % | Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates | ||
ARCELLX | 85,46 | +6,10 % | ACLX, HROW Deliver Triple-Digit Returns - Did You Cash In? | WASHINGTON (dpa-AFX) - Many traders seek instant gratification in the stock market. Some stocks offer quick profits, while others require a patient, long-term approach for significant returns.... ► Artikel lesen | |
STRUCTURE THERAPEUTICS | 38,800 | +1,44 % | Structure Therapeutics Inc.: Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer | SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
MODERNA | 61,03 | -2,97 % | Ihre wichtigsten Termine: Alle Analysten-Augen auf: Moderna, Ryanair, Adobe, Fraport und Baloise | © Foto: Bodo Schackow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 35,320 | -0,70 % | SpringWorks Therapeutics, Inc.: FDA Grants Priority Review to SpringWorks Therapeutics' New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN | - PDUFA target action date of February 28, 2025 - - EU Marketing Authorization Application also validated by European Medicines Agency - STAMFORD, Conn., Aug. 28, 2024 (GLOBE NEWSWIRE) -- SpringWorks... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 6,930 | +0,43 % | Angle PLC Announces Agreement with Recursion Pharmaceuticals | New pharma agreement for Parsortix CTC analysisGUILDFORD, SURREY / ACCESSWIRE / September 19, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating... ► Artikel lesen |